Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL versus SODIUM NITROPRUSSIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL versus SODIUM NITROPRUSSIDE.
MINOXIDIL vs SODIUM NITROPRUSSIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. In hair follicles, it promotes hair growth by increasing blood flow and prolonging the anagen phase, possibly through stimulation of prostaglandin synthesis.
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing cGMP, leading to vasodilation of both arterial and venous vessels.
Oral: 5-40 mg/day in 1-2 divided doses, starting at 5 mg/day and titrating upward; Topical: 1 mL of 2% or 5% solution twice daily.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
None Documented
None Documented
Clinical Note
moderateMinoxidil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid."
Clinical Note
moderateMinoxidil + Furosemide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide."
Clinical Note
moderateMinoxidil + Bumetanide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide."
Clinical Note
moderateMinoxidil + Travoprost
Terminal elimination half-life: 4.2 hours; clinical context: may be prolonged in renal impairment (up to 18 hours), requiring dose adjustment.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Renal: 90% as unchanged drug and metabolites; fecal: 10% via bile.
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator
"Minoxidil may increase the hypotensive activities of Travoprost."